Loading...

Meyskens, Frank L

Title(s)Professor, Medicine
Phone(714) 456-5153
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The 19th Annual Meeting of the Pan American Society for Pigment Cell Research Conference
    NIH/NIAMS R13AR068914Aug 1, 2015 - Jul 31, 2016
    Role: Principal Investigator
    SWOG NCORP Research Base
    NIH/NCI UG1CA189974Aug 1, 2014 - Jul 31, 2025
    Role: Co-Principal Investigator
    7th International Conference on Clinical Cancer Prevention 2012 with Consensus Co
    NIH/NCI R13CA171707Mar 1, 2013 - Feb 28, 2014
    Role: Principal Investigator
    PanAmerican Society for Pigment Cell Research (PASPCR)
    NIH/NCI R13CA110471Jul 16, 2004 - Jul 15, 2005
    Role: Principal Investigator
    Phase I and II Clinical Trials of Agents for Cancer Prevention
    NIH/NCI N01CN35160Sep 30, 2003 - Sep 29, 2009
    Role: Co-Principal Investigator
    Phase III Colon Cancer Prevention Trial
    NIH/NCI R01CA088078Sep 30, 2002 - Aug 31, 2010
    Role: Principal Investigator
    CHEMOPREVENTION OF FAMILIAL PROSTATE CANCER
    NIH/NCI U19CA081886Sep 30, 1999 - Sep 30, 2007
    Role: Principal Investigator
    PHASE II CLINICAL TRIAL OF TOPICAL POLYPHENON E
    NIH/NCI N01CN085182Sep 30, 1998
    Role: Principal Investigator
    Chemoprevention of Oral Cancer with BBIC
    NIH/NCI U01CA072294Mar 14, 1997 - Aug 31, 2010
    Role: Principal Investigator
    PHASE II CLINICAL TRIAL OF DFMO AND NSAIDIN COLON - WORKSTATEMENT 45 -261075019
    NIH/NCI N01CN075019Feb 15, 1997 - Feb 15, 2002
    Role: Co-Principal Investigator
    SIXTEEN INTERNATIONAL PIGMENT CELL CONFERENCE
    NIH/NCI R13CA072887Sep 30, 1996 - Sep 29, 1997
    Role: Principal Investigator
    CLIN CTR CLINICAL TRIAL/OBSERVATIONAL STUDY OF WHI
    NIH/WHI N01WH042107Sep 30, 1994 - Sep 14, 2005
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA062203Aug 15, 1994 - Jan 31, 2021
    Role: Co-Principal Investigator
    SOUTHWEST ONCOLOGY GROUP
    NIH/NCI U10CA058723Aug 1, 1993 - Dec 31, 1997
    Role: Principal Investigator
    POLYAMINE DEPLETION AND CHEMOPREVENTION OF COLON CANCER
    NIH/NCI R01CA059024May 1, 1993 - Feb 28, 1998
    Role: Principal Investigator
    CARET--THE CAROTENE AND RETINOL EFFICACY TRIAL
    NIH/NCI U01CA052596Aug 22, 1991 - Jun 30, 1999
    Role: Principal Investigator
    CHEMOPREVENTION EFFICACY TRIAL OF BETA CAROTENE/RETINOL
    NIH/NCI R01CA052596Aug 22, 1991 - Jun 30, 1995
    Role: Principal Investigator
    CHEMOPREVENTION OF HUMAN MELANOMA
    NIH/NCI U01CA051610Jun 1, 1989 - May 31, 1992
    Role: Principal Investigator
    CHEMOPREVENTION OF HUMAN CANCER
    NIH/NCI R13CA046424Jan 1, 1988 - Dec 31, 1988
    Role: Principal Investigator
    Colon Cancer Prevention Program Project Grant
    NIH/NCI P01CA041108Sep 30, 1986 - Jul 31, 2011
    Role: Co-Principal Investigator
    MODULATION AND MEDIATION OF CANCER BY VITAMINS
    NIH/NCI R13CA038506Feb 6, 1985 - Feb 5, 1986
    Role: Principal Investigator
    SWOG Community Clinical Oncology Program Research Base
    NIH/NCI U10CA037429Sep 30, 1983 - May 31, 2015
    Role: Co-Principal Investigator
    Chemoprevention of Skin Cancer Program Project
    NIH/NCI P01CA027502Jul 22, 1980 - Jun 30, 2016
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Meyskens FL. Abscopal Outcomes: Reflections on Distant Effects. Pract Radiat Oncol. 2019 Sep - Oct; 9(5):294. PMID: 31103714.
      View in: PubMed
    2. Laquer V, Dellinger RW, Mannering I, Garcia AG, Abraham V, Pavlis J, Liu-Smith F, De Feraudy S, Meyskens FL, Kelly KM. 12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2018 Dec; 79(6):1152-1153. PMID: 29902547.
      View in: PubMed
    3. Zecena H, Tveit D, Wang Z, Farhat A, Panchal P, Liu J, Singh SJ, Sanghera A, Bainiwal A, Teo SY, Meyskens FL, Liu-Smith F, Filipp FV. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. BMC Syst Biol. 2018 04 04; 12(1):33. PMID: 29615030.
      View in: PubMed
    4. Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL, Andresen BT, Huang Y. Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. Cancer Prev Res (Phila). 2017 Oct; 10(10):598-606. PMID: 28912118.
      View in: PubMed
    5. Meyskens FL, Liu-Smith F. Redox-Redux and NADPH Oxidase (NOX): Even More Complicated than We Thought it Might Be. J Invest Dermatol. 2017 Jun; 137(6):1208-1210. PMID: 28532757.
      View in: PubMed
    6. Meyskens FL. What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA. J Natl Cancer Inst. 2016 12; 108(12). PMID: 27986883.
      View in: PubMed
    7. Liu-Smith F, Krasieva TB, Liu J, Liu J, Meyskens FL. Measuring Redox Status of Melanoma Cells. Methods Mol Biol. 2016 Apr 10. PMID: 27062599.
      View in: PubMed
    8. Dellinger RW, Meyskens FL. Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells. Methods Mol Biol. 2016 Jan 20. PMID: 26786882.
      View in: PubMed
    9. Meyskens FL. Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals. Cancer Prev Res (Phila). 2016 Jan; 9(1):11-2. PMID: 26701663.
      View in: PubMed
    10. Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst. 2016 Feb; 108(2). PMID: 26547931.
      View in: PubMed
    11. Fabian CJ, Meyskens FL, Bajorin DF, George TJ, Jeter JM, Khan S, Tyne CA, William WN. Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. J Clin Oncol. 2016 Jan 10; 34(2):186-93. PMID: 26527778.
      View in: PubMed
    12. Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL, Wade JL, Hershman DL. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. J Acupunct Meridian Stud. 2015 Jun; 8(3):152-8. PMID: 26100070.
      View in: PubMed
    13. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 05; 372(10):923-32. PMID: 25738668.
      View in: PubMed
    14. Liu-Smith F, Poe C, Farmer PJ, Meyskens FL. Amyloids, melanins and oxidative stress in melanomagenesis. Exp Dermatol. 2015 Mar; 24(3):171-4. PMID: 25271672.
      View in: PubMed
    15. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep; 7(9):886-95. PMID: 24961880.
      View in: PubMed
    16. Dellinger RW, Liu-Smith F, Meyskens FL. Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis. J Photochem Photobiol B. 2014 Sep 05; 138:317-23. PMID: 25022944.
      View in: PubMed
    17. Liu-Smith F, Dellinger R, Meyskens FL. Updates of reactive oxygen species in melanoma etiology and progression. Arch Biochem Biophys. 2014 Dec 01; 563:51-5. PMID: 24780245.
      View in: PubMed
    18. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1494-504. PMID: 24732629.
      View in: PubMed
    19. Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014 May; 7(5):496-504. PMID: 24614012.
      View in: PubMed
    20. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014 Mar; 106(3):djt456. PMID: 24563519.
      View in: PubMed
    21. Meyskens FL, Simoneau AR, Gerner EW. Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine. Recent Results Cancer Res. 2014; 202:115-20. PMID: 24531785.
      View in: PubMed
    22. Dellinger RW, Garcia AM, Meyskens FL. Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab Pharmacokinet. 2014; 29(2):112-9. PMID: 23965644.
      View in: PubMed
    23. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013 Aug 07; 105(15):1132-41. PMID: 23843441.
      View in: PubMed
    24. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013 May; 6(5):410-8. PMID: 23639862.
      View in: PubMed
    25. Xie L, Meyskens FL. The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines. Melanoma Res. 2013 Apr; 23(2):102-13. PMID: 23344158.
      View in: PubMed
    26. Liu F, Bessonova L, Taylor TH, Ziogas A, Meyskens FL, Anton-Culver H. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res. 2013 Jan; 26(1):128-35. PMID: 23095171.
      View in: PubMed
    27. Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. PLoS One. 2012; 7(10):e47696. PMID: 23110092.
      View in: PubMed
    28. Liu F, Gomez Garcia AM, Meyskens FL. NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. J Invest Dermatol. 2012 Aug; 132(8):2033-41. PMID: 22513785.
      View in: PubMed
    29. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12; 306(14):1549-56. PMID: 21990298.
      View in: PubMed
    30. Chu DZ, Hussey MA, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer. 2011 Dec; 10(4):310-6. PMID: 21782524.
      View in: PubMed
    31. Meyskens FL, Gerner EW. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach. Cancer Prev Res (Phila). 2011 May; 4(5):628-32. PMID: 21543341.
      View in: PubMed
    32. Meyskens FL. Therapeutic prevention of colorectal carcinogenesis. J Carcinog. 2011; 10:13. PMID: 21712960.
      View in: PubMed
    33. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011 Mar; 4(3):354-64. PMID: 21372035.
      View in: PubMed
    34. Meyskens FL, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila). 2011 Mar; 4(3):311-23. PMID: 21372031.
      View in: PubMed
    35. Meyskens FL, Yang S. Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in point. Recent Results Cancer Res. 2011; 188:65-74. PMID: 21253789.
      View in: PubMed
    36. Meyskens FL, McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst. 2010 Dec 15; 102(24):1815-7. PMID: 21115881.
      View in: PubMed
    37. Garcia AM, McLaren CE, Meyskens FL. Melanoma: is hair the root of the problem? Pigment Cell Melanoma Res. 2011 Feb; 24(1):110-8. PMID: 20880199.
      View in: PubMed
    38. Liu F, Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL. MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Mol Cancer. 2010 Aug 11; 9:214. PMID: 20701798.
      View in: PubMed
    39. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, Hayes DF, Hooks J, Ling C, Meyskens FL, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR, Vikram B, Zelefsky MJ, Baker LH. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. Clin Cancer Res. 2009 Sep 15; 15(18):5663-70. PMID: 19723641.
      View in: PubMed
    40. Meyskens FL. Food extracts for chemoprevention: quo vadis? Cancer Prev Res (Phila). 2009 Jul; 2(7):608-10. PMID: 19584073.
      View in: PubMed
    41. Gerner EW, Meyskens FL. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 2009 Feb 01; 15(3):758-61. PMID: 19188144.
      View in: PubMed
    42. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51. PMID: 19066370.
      View in: PubMed
    43. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther. 2008 Dec; 7(12):3751-60. PMID: 19074850.
      View in: PubMed
    44. McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila). 2008 Dec; 1(7):514-21. PMID: 19139001.
      View in: PubMed
    45. Liu F, Fu Y, Meyskens FL. MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J Invest Dermatol. 2009 Feb; 129(2):422-31. PMID: 18971960.
      View in: PubMed
    46. Yang S, Misner B, Chiu R, Meyskens FL. Common and distinct mechanisms of different redox-active carcinogens involved in the transformation of mouse JB6P+ cells. Mol Carcinog. 2008 Jul; 47(7):485-91. PMID: 18092320.
      View in: PubMed
    47. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8. PMID: 18841250.
      View in: PubMed
    48. Gidanian S, Mentelle M, Meyskens FL, Farmer PJ. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake--a basis for the pro-oxidant state of melanoma. Photochem Photobiol. 2008 May-Jun; 84(3):556-64. PMID: 18331399.
      View in: PubMed
    49. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):292-9. PMID: 18268112.
      View in: PubMed
    50. Meyskens FL, Berwick M. UV or not UV: metals are the answer. Cancer Epidemiol Biomarkers Prev. 2008 Feb; 17(2):268-70. PMID: 18268109.
      View in: PubMed
    51. Ngo-Metzger Q, August KJ, Srinivasan M, Liao S, Meyskens FL. End-of-Life care: guidelines for patient-centered communication. Am Fam Physician. 2008 Jan 15; 77(2):167-74. PMID: 18246886.
      View in: PubMed
    52. Meyskens FL. Another negative chemoprevention trial: what can we learn? Clin Cancer Res. 2008 Jan 01; 14(1):2-3. PMID: 18172244.
      View in: PubMed
    53. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008 Jan 01; 26(1):66-75. PMID: 18165642.
      View in: PubMed
    54. Yang S, Misner BJ, Chiu RJ, Meyskens FL. Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells. Carcinogenesis. 2007 Nov; 28(11):2382-90. PMID: 17566060.
      View in: PubMed
    55. Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW, Meyskens FL. Development of a polyamine database for assessing dietary intake. J Am Diet Assoc. 2007 Jun; 107(6):1024-7. PMID: 17524725.
      View in: PubMed
    56. Gerner EW, Meyskens FL, Goldschmid S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids. 2007 Aug; 33(2):189-95. PMID: 17396214.
      View in: PubMed
    57. Meyskens F. Cancer following total joint arthroplasty. Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):356. PMID: 17301272.
      View in: PubMed
    58. Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007 Feb 01; 13(3):789-94. PMID: 17289868.
      View in: PubMed
    59. Ghajar CM, Suresh V, Peyton SR, Raub CB, Meyskens FL, George SC, Putnam AJ. A novel three-dimensional model to quantify metastatic melanoma invasion. Mol Cancer Ther. 2007 Feb; 6(2):552-61. PMID: 17267658.
      View in: PubMed
    60. Meyskens FL, Farmer PJ, Yang S, Anton-Culver H. New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res. 2007; 174:191-5. PMID: 17302196.
      View in: PubMed
    61. Meyskens FL. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development. Cancer Epidemiol Biomarkers Prev. 2006 Nov; 15(11):2038-41. PMID: 17119025.
      View in: PubMed
    62. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      View in: PubMed
    63. Meyskens FL, Ransohoff DF. Predicting risk for the appearance of melanoma. J Clin Oncol. 2006 Aug 01; 24(22):3522-3. PMID: 16728487.
      View in: PubMed
    64. Goding C, Meyskens FL. Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. Clin Cancer Res. 2006 Feb 15; 12(4):1069-73. PMID: 16489058.
      View in: PubMed
    65. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther. 2005 Dec; 4(12):1923-35. PMID: 16373707.
      View in: PubMed
    66. Meyskens FL, Tully P. Principles of cancer prevention. Semin Oncol Nurs. 2005 Nov; 21(4):229-35. PMID: 16293510.
      View in: PubMed
    67. Meyskens FL, Hietanen P, Tannock IF. Talking to a patient. J Clin Oncol. 2005 Jul 01; 23(19):4463-4. PMID: 15994158.
      View in: PubMed
    68. Meyskens FL, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1366-9. PMID: 15941942.
      View in: PubMed
    69. McEligot AJ, Yang S, Meyskens FL. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu Rev Nutr. 2005; 25:261-95. PMID: 16011468.
      View in: PubMed
    70. Meyskens FL, Szabo E. How should we move the field of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res. 2005; 166:113-24. PMID: 15648187.
      View in: PubMed
    71. Meyskens FL, Farmer PJ, Anton-Culver H. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev. 2005 Jan; 14(1):293. PMID: 15668513.
      View in: PubMed
    72. Cen D, Brayton D, Shahandeh B, Meyskens FL, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem. 2004 Dec 30; 47(27):6914-20. PMID: 15615540.
      View in: PubMed
    73. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. Cancer Epidemiol Biomarkers Prev. 2004 Dec; 13(12):1996-2002. PMID: 15598753.
      View in: PubMed
    74. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL, Omenn GS, Valanis B, Williams JH. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004 Dec 01; 96(23):1743-50. PMID: 15572756.
      View in: PubMed
    75. Yang S, Meyskens FL. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol Pharmacol. 2005 Jan; 67(1):298-308. PMID: 15492115.
      View in: PubMed
    76. Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004 Oct; 4(10):781-92. PMID: 15510159.
      View in: PubMed
    77. Meyskens FL, Fetting JH. Pulling the trigger. J Clin Oncol. 2004 Sep 01; 22(17):3644-5. PMID: 15337815.
      View in: PubMed
    78. Meyskens FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res. 2004 Apr 15; 10(8):2581-3. PMID: 15102657.
      View in: PubMed
    79. McNulty SE, del Rosario R, Cen D, Meyskens FL, Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004 Apr; 17(2):173-80. PMID: 15016307.
      View in: PubMed
    80. Yang S, McNulty S, Meyskens FL. During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. Pigment Cell Res. 2004 Feb; 17(1):74-83. PMID: 14717848.
      View in: PubMed
    81. Follen M, Meyskens FL, Alvarez RD, Walker JL, Bell MC, Storthz KA, Sastry J, Roy K, Richards-Kortum R, Cornelison TL. Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Cancer. 2003 Nov 01; 98(9 Suppl):2044-51. PMID: 14603541.
      View in: PubMed
    82. Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope. 2003 Oct; 113(10):1687-702. PMID: 14520092.
      View in: PubMed
    83. Chu DZ, Chansky K, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman SM. Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. Ann Surg Oncol. 2003 Oct; 10(8):870-5. PMID: 14527904.
      View in: PubMed
    84. Armstrong WB, Taylor TH, Meyskens FL. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):589-92. PMID: 12869395.
      View in: PubMed
    85. Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL. Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res. 2003 Jun; 16(3):273-9. PMID: 12753401.
      View in: PubMed
    86. Meyskens FL. Management of human melanoma: what has the last decade wrought? Oncologist. 2003; 8(5):448-50. PMID: 14530497.
      View in: PubMed
    87. Follen M, Vlastos AT, Meyskens FL, Atkinson EN, Schottenfeld D. Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes Control. 2002 Nov; 13(9):855-73. PMID: 12462551.
      View in: PubMed
    88. Meyskens FL. Chemoprevention of FAP with sulindac. Curr Oncol Rep. 2002 Nov; 4(6):463. PMID: 12385292.
      View in: PubMed
    89. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther. 2002 Jan; 1(3):197-204. PMID: 12467214.
      View in: PubMed
    90. Meyskens FL. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann N Y Acad Sci. 2001 Dec; 952:116-23. PMID: 11795430.
      View in: PubMed
    91. McNulty SE, Tohidian NB, Meyskens FL. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res. 2001 Dec; 14(6):456-65. PMID: 11775058.
      View in: PubMed
    92. Meyskens FL, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med. 2001 Sep 15; 31(6):799-808. PMID: 11557318.
      View in: PubMed
    93. Follen M, Meyskens FL, Atkinson EN, Schottenfeld D. Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. J Natl Cancer Inst. 2001 Sep 05; 93(17):1293-6. PMID: 11535703.
      View in: PubMed
    94. Meyskens FL, Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma. Pigment Cell Res. 2001 Jun; 14(3):148-54. PMID: 11434561.
      View in: PubMed
    95. Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 2001 Apr; 57(4 Suppl 1):4-27. PMID: 11295590.
      View in: PubMed
    96. Powell IJ, Meyskens FL. African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urology. 2001 Apr; 57(4 Suppl 1):178-81. PMID: 11295621.
      View in: PubMed
    97. Klein EA, Meyskens FL. Potential target populations and clinical models for testing chemopreventive agents. Urology. 2001 Apr; 57(4 Suppl 1):171-3. PMID: 11295619.
      View in: PubMed
    98. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL. Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst. 2001 Jan 03; 93(1):57-9. PMID: 11136843.
      View in: PubMed
    99. Meyskens FL. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned. IARC Sci Publ. 2001; 154:49-55. PMID: 11220668.
      View in: PubMed
    100. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res. 2000 Dec; 6(12):4684-91. PMID: 11156220.
      View in: PubMed
    101. Meyskens FL. Cancer prevention in the year 2025: an anticipation. Eur J Cancer. 2000 Sep; 36(14):1737-40. PMID: 10974620.
      View in: PubMed
    102. Moinpour CM, Sawyers Triplett J, McKnight B, Lovato LC, Upchurch C, Leichman CG, Muggia FM, Tanaka L, James WA, Lennard M, Meyskens FL. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology. 2000 Jul-Aug; 9(4):340-54. PMID: 10960931.
      View in: PubMed
    103. Meyskens FL. Cancer population genetics and tumour prevention: an unfulfilled paradigm. Eur J Cancer. 2000 Jun; 36(10):1189-92. PMID: 10882855.
      View in: PubMed
    104. Meyskens FL, Jungi WF, Gerber M, de Waard F, Heidemann E, Heim ME, Joossens JV, Salvini S, Trichopoulou A, Varela G, Wolfram G. WHO consensus conference on diet and cancer. Members of the breast cancer panel. Eur J Cancer Prev. 2000 Jun; 9(3):213-6. PMID: 10954261.
      View in: PubMed
    105. Armstrong WB, Meyskens FL. Chemoprevention of head and neck cancer. Otolaryngol Head Neck Surg. 2000 May; 122(5):728-35. PMID: 10793355.
      View in: PubMed
    106. Meyskens FL. Chemoprevention of breast and colon cancer. Curr Oncol Rep. 2000 May; 2(3):223-4. PMID: 11122846.
      View in: PubMed
    107. Meyskens FL. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete? J Natl Cancer Inst. 2000 Feb 02; 92(3):274-5. PMID: 10655448.
      View in: PubMed
    108. Meyskens FL. Criteria for implementation of large and multiagent clinical chemoprevention trials. J Cell Biochem Suppl. 2000; 34:115-20. PMID: 10762023.
      View in: PubMed
    109. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev. 2000 Jan; 9(1):43-7. PMID: 10667462.
      View in: PubMed
    110. Wan XS, Meyskens FL, Armstrong WB, Taylor TH, Kennedy AR. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomarkers Prev. 1999 Jul; 8(7):601-8. PMID: 10428197.
      View in: PubMed
    111. Meyskens FL, Buckmeier JA, McNulty SE, Tohidian NB. Activation of nuclear factor-kappa B in human metastatic melanomacells and the effect of oxidative stress. Clin Cancer Res. 1999 May; 5(5):1197-202. PMID: 10353757.
      View in: PubMed
    112. Meyskens FL, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 1999 May; 5(5):945-51. PMID: 10353725.
      View in: PubMed
    113. Meyskens FL. Re: Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1999 Mar 17; 91(6):563-5. PMID: 10088631.
      View in: PubMed
    114. Meyskens FL. Chemoprevention of human cancer: a reasonable strategy? Recent Results Cancer Res. 1999; 151:113-21. PMID: 10337722.
      View in: PubMed
    115. Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, Taylor SA, Balcerzak SP, Meyskens FL. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am. 1999 Jan-Feb; 5(1):41-7. PMID: 10188060.
      View in: PubMed
    116. Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, Higgins B, Skeel R, Yee M, Blumenstein BA, Crawford ED, Meyskens FL. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1998 Oct 21; 90(20):1537-44. PMID: 9790546.
      View in: PubMed
    117. Meyskens FL. Principles of human chemoprevention. Hematol Oncol Clin North Am. 1998 Oct; 12(5):935-41, v. PMID: 9888014.
      View in: PubMed
    118. Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst. 1998 Aug 19; 90(16):1212-8. PMID: 9719082.
      View in: PubMed
    119. Goodman GE, Valanis B, Meyskens FL, Williams JH, Metch BJ, Thornquist MD, Omenn GS. Strategies for recruitment to a population-based lung cancer prevention trial: the CARET experience with heavy smokers. Beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 1998 May; 7(5):405-12. PMID: 9610790.
      View in: PubMed
    120. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998 Mar 15; 58(6):1149-58. PMID: 9515799.
      View in: PubMed
    121. Meyskens FL, Jacobson J, Nguyen B, Weiss GR, Gandara DR, MacDonald JS. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs. 1998; 16(2):171-3. PMID: 9848581.
      View in: PubMed
    122. Meyskens FL, Chau HV, Tohidian N, Buckmeier J. Luminol-enhanced chemiluminescent response of human melanocytes and melanoma cells to hydrogen peroxide stress. Pigment Cell Res. 1997 Jun; 10(3):184-9. PMID: 9266607.
      View in: PubMed
    123. Strickland CJ, Feigl P, Upchurch C, King DK, Pierce HI, Grevstad PK, Bearden JD, Dawson M, Loewen WC, Meyskens FL. Improving breast self-examination compliance: a Southwest Oncology Group randomized trial of three interventions. Prev Med. 1997 May-Jun; 26(3):320-32. PMID: 9144756.
      View in: PubMed
    124. Atiba JO, Manzardo AM, Thiruvengadam R, Schell MJ, Meyskens FL. Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. Am J Ther. 1997 Apr; 4(4):134-40. PMID: 10423603.
      View in: PubMed
    125. Gordon W, Siegmund K, Stanisic TH, McKnight B, Harris IT, Carroll PR, Paradelo JC, Meyers FJ, Chapman RA, Meyskens FL. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):83-94. PMID: 9212008.
      View in: PubMed
    126. Atiba JO, Meyskens FL. Correction--malignant glioma. J Clin Oncol. 1997 Mar; 15(3):1286-7. PMID: 9060576.
      View in: PubMed
    127. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Cherniack MG, Brodkin CA, Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996 Nov 06; 88(21):1550-9. PMID: 8901853.
      View in: PubMed
    128. Omenn GS, Goodman G, Thornquist M, Barnhart S, Balmes J, Cherniack M, Cullen M, Glass A, Keogh J, Liu D, Meyskens F, Perloff M, Valanis B, Williams J. Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers. IARC Sci Publ. 1996; (136):67-85. PMID: 8791118.
      View in: PubMed
    129. Meyskens FL, Manetta A. Prevention of cervical intraepithelial neoplasia and cervical cancer. Am J Clin Nutr. 1995 12; 62(6 Suppl):1417S-1419S. PMID: 7495240.
      View in: PubMed
    130. Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 1995 Nov 15; 87(22):1710-3. PMID: 7473820.
      View in: PubMed
    131. Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res. 1995 Sep; 19(9):605-12. PMID: 7564470.
      View in: PubMed
    132. Childers JM, Chu J, Voigt LF, Feigl P, Tamimi HK, Franklin EW, Alberts DS, Meyskens FL. Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev. 1995 Mar; 4(2):155-9. PMID: 7742723.
      View in: PubMed
    133. Meyskens FL, Gerner EW. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. J Cell Biochem Suppl. 1995; 22:126-31. PMID: 8538189.
      View in: PubMed
    134. Jakowatz JG, Meyskens FL. Evaluation and treatment of the patient with early melanoma. Compr Ther. 1995; 21(1):46-50. PMID: 7697982.
      View in: PubMed
    135. Meyskens FL, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2060-5. PMID: 7931474.
      View in: PubMed
    136. Meyskens FL, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst. 1994 Aug 03; 86(15):1122-30. PMID: 8028034.
      View in: PubMed
    137. Meyskens FL, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst. 1994 Apr 06; 86(7):539-43. PMID: 8133537.
      View in: PubMed
    138. Aickin M, Ritenbaugh C, Surwit E, Meyskens F. Comparative exposure ratios: a non-parametric, multifactor technique for case-control studies. Stat Med. 1994 Feb 15; 13(3):245-60. PMID: 8202651.
      View in: PubMed
    139. Yamanishi DT, Meyskens FL. Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Crit Rev Oncog. 1994; 5(5):429-50. PMID: 8519807.
      View in: PubMed
    140. Garewal H, Meyskens F, Friedman S, Alberts D, Ramsey L. Oral cancer prevention: the case for carotenoids and anti-oxidant nutrients. Prev Med. 1993 Sep; 22(5):701-11. PMID: 8234210.
      View in: PubMed
    141. Back SA, Colon M, Fallon JH, Meyskens FL, Loughlin SE. Ventral mesencephalic and cortical transplants into the rat striatum display enhanced activity for neutral endopeptidase 24.11 ('enkephalinase'; CALLA). Brain Res. 1993 May 28; 612(1-2):85-95. PMID: 8330216.
      View in: PubMed
    142. Meyskens FL. Retinoids as anticancer agents. J Clin Oncol. 1993 Mar; 11(3):588-9. PMID: 8445437.
      View in: PubMed
    143. Powell MB, Rosenberg RK, Graham MJ, Birch ML, Yamanishi DT, Buckmeier JA, Meyskens FL. Protein kinase C beta expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate. J Cancer Res Clin Oncol. 1993; 119(4):199-206. PMID: 7678596.
      View in: PubMed
    144. Hickie RA, Graham MJ, Buckmeier JA, Meyskens FL. Comparison of calmodulin gene expression in human neonatal melanocytes and metastatic melanoma cell lines. J Invest Dermatol. 1992 Dec; 99(6):764-73. PMID: 1469290.
      View in: PubMed
    145. Yamanishi DT, Graham MJ, Florkiewicz RZ, Buckmeier JA, Meyskens FL. Differences in basic fibroblast growth factor RNA and protein levels in human primary melanocytes and metastatic melanoma cells. Cancer Res. 1992 Sep 15; 52(18):5024-9. PMID: 1516057.
      View in: PubMed
    146. Atiba JO, Meyskens FL. Chemoprevention of breast cancer. Semin Oncol. 1992 Jun; 19(3):220-9. PMID: 1609290.
      View in: PubMed
    147. Meyskens FL. Isn't skin cancer preventable? J Natl Cancer Inst. 1992 Mar 04; 84(5):286-7. PMID: 1738176.
      View in: PubMed
    148. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst. 1992 Feb 05; 84(3):165-74. PMID: 1371813.
      View in: PubMed
    149. Meyskens FL. Strategies for prevention of cancer in humans. Oncology (Williston Park). 1992 Feb; 6(2 Suppl):15-24. PMID: 1532731.
      View in: PubMed
    150. Garewal HS, Meyskens F. Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. Cancer Epidemiol Biomarkers Prev. 1992 Jan-Feb; 1(2):155-9. PMID: 1306099.
      View in: PubMed
    151. Meyskens FL. Biomarker intermediate endpoints and cancer prevention. J Natl Cancer Inst Monogr. 1992; (13):177-81. PMID: 1389691.
      View in: PubMed
    152. Boyle JO, Meyskens FL, Garewal HS, Gerner EW. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 1992 Jan-Feb; 1(2):131-5. PMID: 1306095.
      View in: PubMed
    153. Lippman SM, Bassford TL, Meyskens FL. A quantitatively scored cancer-risk assessment tool: its development and use. J Cancer Educ. 1992; 7(1):15-36. PMID: 1571244.
      View in: PubMed
    154. Yamanishi DT, Buckmeier JA, Meyskens FL. Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas. J Invest Dermatol. 1991 Aug; 97(2):349-53. PMID: 1712822.
      View in: PubMed
    155. Ho EE, Atwood JR, Benedict J, Ritenbaugh C, Sheehan ET, Abrams C, Alberts D, Meyskens FL. A community-based feasibility study using wheat bran fiber supplementation to lower colon cancer risk. Prev Med. 1991 Mar; 20(2):213-25. PMID: 1647531.
      View in: PubMed
    156. Garewal HS, Meyskens FL. Chemoprevention of cancer. Hematol Oncol Clin North Am. 1991 Feb; 5(1):69-77. PMID: 2026569.
      View in: PubMed
    157. Loescher LJ, Meyskens FL. Chemoprevention of human skin cancers. Semin Oncol Nurs. 1991 Feb; 7(1):45-52. PMID: 2011658.
      View in: PubMed
    158. Ho EE, Lee FC, Meyskens FL. An exploratory study of attitudes, beliefs and practices related to the interim dietary guidelines for reducing cancer in the elderly. J Nutr Elder. 1991; 10(4):31-49. PMID: 1920044.
      View in: PubMed
    159. Yamanishi DT, Graham M, Buckmeier JA, Meyskens FL. The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis. 1991 Jan; 12(1):105-9. PMID: 1988168.
      View in: PubMed
    160. Garewal H, Meyskens FL. Beta-carotene didn't prevent cancer: what's up doc? J Natl Cancer Inst. 1990 Dec 05; 82(23):1851-3. PMID: 2078244.
      View in: PubMed
    161. Garewal HS, Meyskens FL, Killen D, Reeves D, Kiersch TA, Elletson H, Strosberg A, King D, Steinbronn K. Response of oral leukoplakia to beta-carotene. J Clin Oncol. 1990 Oct; 8(10):1715-20. PMID: 2213107.
      View in: PubMed
    162. Meyskens FL. Coming of age--the chemoprevention of cancer. N Engl J Med. 1990 Sep 20; 323(12):825-7. PMID: 2202903.
      View in: PubMed
    163. Yohem KH, Slymen DJ, Bregman MD, Meyskens FL. Radiosensitivity of murine and human melanoma cells: a comparative study with different models. Pigment Cell Res. 1990 Sep; 3(3):157-61. PMID: 2290787.
      View in: PubMed
    164. Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs. 1990 Aug; 8(3):317-9. PMID: 2148744.
      View in: PubMed
    165. Harari PM, Fuller DJ, Carper SW, Croghan MK, Meyskens FL, Shimm DS, Gerner EW. Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy. Int J Radiat Oncol Biol Phys. 1990 Jul; 19(1):89-96. PMID: 2116388.
      View in: PubMed
    166. Yohem KH, Bregman MD, Meyskens FL. Effect of single dose ionizing radiation on the cellular proliferation and apparent radiosensitivity of melanoma. Anticancer Res. 1990 Jul-Aug; 10(4):1079-82. PMID: 2382980.
      View in: PubMed
    167. Meyskens FL, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J, Coltman C. Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1071. PMID: 2112201.
      View in: PubMed
    168. Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Ocular toxic effects of fenretinide. J Natl Cancer Inst. 1990 Jun 20; 82(12):1063. PMID: 2140863.
      View in: PubMed
    169. Meyskens FL. The place of chemoprevention studies in cancer prevention planning. Prog Clin Biol Res. 1990; 346:135-43. PMID: 2197622.
      View in: PubMed
    170. Loescher LJ, Graham VE, Aickin M, Meyskens FL, Surwit EA. Development of a contingency recruitment plan for a phase III chemoprevention trial of cervical dysplasia. Prog Clin Biol Res. 1990; 339:151-63. PMID: 2202990.
      View in: PubMed
    171. Meyskens FL, Thomson SP, Buckmeier J. Replating efficiency of metastatic melanoma cells from lymph node and subcutaneous sites does not predict patient survival. Clin Exp Metastasis. 1989 Nov-Dec; 7(6):627-32. PMID: 2776367.
      View in: PubMed
    172. Welch-McCaffrey D, Hoffman B, Leigh SA, Loescher LJ, Meyskens FL. Surviving adult cancers. Part 2: Psychosocial implications. Ann Intern Med. 1989 Sep 15; 111(6):517-24. PMID: 2672926.
      View in: PubMed
    173. Loescher LJ, Welch-McCaffrey D, Leigh SA, Hoffman B, Meyskens FL. Surviving adult cancers. Part 1: Physiologic effects. Ann Intern Med. 1989 Sep 01; 111(5):411-32. PMID: 2669594.
      View in: PubMed
    174. Plezia PM, Alberts DS, Peng YM, Xu MJ, Sayers S, Davis TP, Surwit EA, Meyskens FL. The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Prev Med. 1989 Sep; 18(5):680-7. PMID: 2694162.
      View in: PubMed
    175. Lippman SM, Garewal HS, Meyskens FL. Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck. Prev Med. 1989 Sep; 18(5):740-8. PMID: 2694167.
      View in: PubMed
    176. Yohem KH, Seftor EA, Meyskens FL, Hendrix MJ. Cloning efficiency of human melanoma cells is modulated after invasion through a reconstituted basement membrane. Cancer Lett. 1989 May; 45(2):135-43. PMID: 2731157.
      View in: PubMed
    177. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst. 1989 Apr 05; 81(7):485-95. PMID: 2646455.
      View in: PubMed
    178. Berdeaux DH, Meyskens FL, Parks B, Tong T, Loescher L, Moon TE. Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease. Cancer. 1989 Apr 01; 63(7):1430-6. PMID: 2920369.
      View in: PubMed
    179. Persky B, Meyskens FL, Hendrix MJ. Immunohistochemical and ultrastructural study of human melanoma colonies grown in soft agar. Am J Anat. 1989 Mar; 184(3):212-24. PMID: 2750677.
      View in: PubMed
    180. Trent JM, Thompson FH, Meyskens FL. Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma. Cancer Res. 1989 Jan 15; 49(2):420-3. PMID: 2642739.
      View in: PubMed
    181. Peng YM, Dalton WS, Alberts DS, Xu MJ, Lim H, Meyskens FL. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer. 1989 Jan 15; 43(1):22-6. PMID: 2521335.
      View in: PubMed
    182. Lippman SM, Meyskens FL. Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmacol Ther. 1989; 40(1):107-22. PMID: 2645584.
      View in: PubMed
    183. Meyskens FL. Evolution of Cancer Prevention and Control Program at the Arizona Cancer Center. J Natl Cancer Inst. 1988 Dec 21; 80(20):1595-8. PMID: 3193477.
      View in: PubMed
    184. Meyskens FL. Thinking about cancer causality and chemoprevention. J Natl Cancer Inst. 1988 Oct 19; 80(16):1278-81. PMID: 3172255.
      View in: PubMed
    185. Meyskens FL, Berdeaux DH, Parks B, Tong T, Loescher L, Moon TE. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer. 1988 Sep 15; 62(6):1207-14. PMID: 3409189.
      View in: PubMed
    186. Croghan MK, Booth A, Meyskens FL. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma. J Biol Response Mod. 1988 Aug; 7(4):409-15. PMID: 3139843.
      View in: PubMed
    187. Bregman MD, Meyskens FL. Human recombinant alpha- and gamma-interferons enhance the cytotoxic properties of tumor necrosis factor on human melanoma. J Biol Response Mod. 1988 Aug; 7(4):384-9. PMID: 3139842.
      View in: PubMed
    188. Lippman SM, Shimm DS, Meyskens FL. Nonsurgical treatments for skin cancer: retinoids and alpha-interferon. J Dermatol Surg Oncol. 1988 Aug; 14(8):862-9. PMID: 3294268.
      View in: PubMed
    189. Lippman SM, Meyskens FL. Vitamin A derivatives in the prevention and treatment of human cancer. J Am Coll Nutr. 1988 Aug; 7(4):269-84. PMID: 3062055.
      View in: PubMed
    190. Meyskens FL. Rethinking medical oncology training and education. J Clin Oncol. 1988 Mar; 6(3):561-2. PMID: 3351562.
      View in: PubMed
    191. Meyskens FL. Biology of human melanoma colony-forming cells. Prog Clin Biol Res. 1988; 256:325-32. PMID: 3368492.
      View in: PubMed
    192. Yohem KH, Slymen DJ, Bregman MD, Meyskens FL. Radiation survival of murine and human melanoma cells utilizing two assay systems: monolayer and soft agar. Br J Cancer. 1988 Jan; 57(1):64-9. PMID: 3348949.
      View in: PubMed
    193. Lippman SM, Meyskens FL. Retinoids as anticancer agents. Prog Clin Biol Res. 1988; 259:229-44. PMID: 3283747.
      View in: PubMed
    194. Bregman MD, Buckmeier J, Meyskens FL. Tetrazolium staining by optical scanning overestimates colony size and number of colonies counted. Int J Cell Cloning. 1987 Nov; 5(6):472-9. PMID: 3429933.
      View in: PubMed
    195. Yohem KH, Bregman MD, Meyskens FL. Effect of tumor colony definition on ionizing radiation survival curves of melanoma-colony forming cells. Int J Radiat Oncol Biol Phys. 1987 Nov; 13(11):1725-33. PMID: 3667379.
      View in: PubMed
    196. Lippman SM, Meyskens FL. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med. 1987 Oct; 107(4):499-502. PMID: 3477106.
      View in: PubMed
    197. Bertram JS, Kolonel LN, Meyskens FL. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res. 1987 Jun 01; 47(11):3012-31. PMID: 3105872.
      View in: PubMed
    198. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep. 1987 May; 71(5):493-515. PMID: 3552220.
      View in: PubMed
    199. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep. 1987 Apr; 71(4):391-405. PMID: 3548957.
      View in: PubMed
    200. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987 Feb; 123(2):201-4. PMID: 2949706.
      View in: PubMed
    201. Bregman MD, Buckmeier J, Funk C, Meyskens FL. Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells. Pigment Cell Res. 1987; 1(2):124-8. PMID: 3148916.
      View in: PubMed
    202. Ho EE, Atwood JR, Meyskens FL. Methodological development of dietary fiber intervention to lower colon cancer risk. Prog Clin Biol Res. 1987; 248:263-81. PMID: 2823286.
      View in: PubMed
    203. Meyskens FL, Surwit ES. Clinical experience with topical tretinoin in the treatment of cervical dysplasia. J Am Acad Dermatol. 1986 Oct; 15(4 Pt 2):826-9. PMID: 3534021.
      View in: PubMed
    204. Meyskens FL, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol. 1986 Oct; 15(4 Pt 2):822-5. PMID: 3534020.
      View in: PubMed
    205. Graham V, Surwit ES, Weiner S, Meyskens FL. Phase II trial of beta-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. West J Med. 1986 Aug; 145(2):192-5. PMID: 3765597.
      View in: PubMed
    206. Mackel C, Meyskens FL, Alberts DS. Phase II trial of bisantrene in patients with metastatic melanoma. Cancer Treat Rep. 1986 Aug; 70(8):1037-8. PMID: 3731151.
      View in: PubMed
    207. Greenberg BR, Buzaid AC, Meyskens FL. 13-cis-retinoic acid in myelodysplastic syndromes. J Clin Oncol. 1986 Aug; 4(8):1282. PMID: 3525772.
      View in: PubMed
    208. Sipes NJ, Meyskens FL, Bregman MD. Biological characterization of an acid-sensitive growth factor from human platelets: role in the proliferation of human melanoma and bovine endothelial cells. Biochem Biophys Res Commun. 1986 Jul 31; 138(2):795-802. PMID: 3741434.
      View in: PubMed
    209. Abdel Malek ZA, Hadley ME, Bregman MD, Meyskens FL, Hruby VJ. Actions of melanotropins on mouse melanoma cell growth in vitro. J Natl Cancer Inst. 1986 May; 76(5):857-63. PMID: 3009949.
      View in: PubMed
    210. Alberts DS, Coulthard SW, Meyskens FL. Regression of aggressive laryngeal papillomatosis with 13-cis-retinoic acid (accutane). J Biol Response Mod. 1986 Apr; 5(2):124-8. PMID: 3461133.
      View in: PubMed
    211. Bregman MD, Meyskens FL. Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. Int J Cancer. 1986 Jan 15; 37(1):101-7. PMID: 3079741.
      View in: PubMed
    212. Weiner SA, Surwit EA, Graham VE, Meyskens FL. A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Invest New Drugs. 1986; 4(3):241-4. PMID: 3818228.
      View in: PubMed
    213. Peng YM, Alberts DS, Graham V, Surwit EA, Weiner S, Meyskens FL. Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia. Invest New Drugs. 1986; 4(3):245-9. PMID: 3818229.
      View in: PubMed
    214. Sipes NJ, Bregman MD, Meyskens FL. Stimulation of human metastatic melanoma colony-forming cells by an acid-sensitive factor in human platelet sonicate. Cancer Res. 1985 Dec; 45(12 Pt 1):6268-72. PMID: 3864528.
      View in: PubMed
    215. Greenberg BR, Durie BG, Barnett TC, Meyskens FL. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep. 1985 Dec; 69(12):1369-74. PMID: 3865701.
      View in: PubMed
    216. Hendrix MJ, Gehlsen KR, Wagner HN, Rodney SR, Misiorowski RL, Meyskens FL. In vitro quantification of melanoma tumor cell invasion. Clin Exp Metastasis. 1985 Oct-Dec; 3(4):221-33. PMID: 4075611.
      View in: PubMed
    217. Bregman MD, Abdel Malek ZA, Meyskens FL. Anchorage-independent growth of murine melanoma in serum-less media is dependent on insulin or melanocyte-stimulating hormone. Exp Cell Res. 1985 Apr; 157(2):419-28. PMID: 3920061.
      View in: PubMed
    218. Kreutzfeld KL, Lei KY, Bregman MD, Meyskens FL. Dexamethasone and zinc in combination inhibit the anchorage-independent growth of S-91 Cloudman murine melanoma. Life Sci. 1985 Mar 04; 36(9):823-7. PMID: 3974412.
      View in: PubMed
    219. Meyskens FL, Thomson SP, Moon TE. Similar self-renewal properties for different sizes of human primary melanoma colonies replated in agar. Cancer Res. 1985 Mar; 45(3):1101-7. PMID: 3882224.
      View in: PubMed
    220. Meyskens FL, Goodman GE, Alberts DS. 13-Cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. Crit Rev Oncol Hematol. 1985; 3(1):75-101. PMID: 3893773.
      View in: PubMed
    221. Meyskens FL, Loescher L, Moon TE, Takasugi B, Salmon SE. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. J Clin Oncol. 1984 Nov; 2(11):1223-8. PMID: 6387058.
      View in: PubMed
    222. Thomson SP, Moon TE, Meyskens FL. Kinetics of clonogenic melanoma cell proliferation and the limits on growth within a bilayer agar system. J Cell Physiol. 1984 Oct; 121(1):114-24. PMID: 6480705.
      View in: PubMed
    223. Levine N, Miller RC, Meyskens FL. Oral isotretinoin therapy. Use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas. Arch Dermatol. 1984 Sep; 120(9):1215-7. PMID: 6591861.
      View in: PubMed
    224. Meyskens FL, Thomson SP, Moon TE. Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res. 1984 Jan; 44(1):271-7. PMID: 6690038.
      View in: PubMed
    225. Meyskens FL, Thomson SP, Hickie RA, Sipes NJ. Potential biological explanation of stimulation of colony growth in semi-solid agar by cytotoxic agents. Br J Cancer. 1983 Dec; 48(6):863-8. PMID: 6360194.
      View in: PubMed
    226. Meyskens FL, Graham V, Chvapil M, Dorr RT, Alberts DS, Surwit EA. A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst. 1983 Nov; 71(5):921-5. PMID: 6580493.
      View in: PubMed
    227. Bregman MD, Peters E, Sander D, Meyskens FL. Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar. J Natl Cancer Inst. 1983 Nov; 71(5):927-32. PMID: 6580494.
      View in: PubMed
    228. Berdeaux DH, Moon TE, Meyskens FL. Management of Stage I cutaneous melanoma. Ariz Med. 1983 Nov; 40(11):768-72. PMID: 6661064.
      View in: PubMed
    229. Meyskens FL, Alberts DS, Salmon SE. Effect of 13-cis-retinoic acid and 4-hydroxyphenyl-all-trans-retinamide on human tumor colony formation in soft agar. Int J Cancer. 1983 Sep 15; 32(3):295-9. PMID: 6224747.
      View in: PubMed
    230. Kummet T, Meyskens FL. Vitamin A: a potential inhibitor of human cancer. Semin Oncol. 1983 Sep; 10(3):281-9. PMID: 6364353.
      View in: PubMed
    231. Bregman MD, Meyskens FL. In vitro modulation of human and murine melanoma growth by prostanoid analogues. Prostaglandins. 1983 Sep; 26(3):449-56. PMID: 6581509.
      View in: PubMed
    232. Meyskens FL. Radiation sensitivity of clonogenic human melanoma cells. Lancet. 1983 Jul 23; 2(8343):219. PMID: 6135052.
      View in: PubMed
    233. Ahmann FR, Meyskens FL, Jones SE, Bukowski RM, Saiers JH, Ryan DH, Costanzi J, Vaughn CB, Coltman CA. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. Cancer Treat Rep. 1983 Jul-Aug; 67(7-8):697-700. PMID: 6688199.
      View in: PubMed
    234. Kessler JF, Meyskens FL, Levine N, Lynch PJ, Jones SE. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983 Jun 18; 1(8338):1345-7. PMID: 6134133.
      View in: PubMed
    235. Bregman MD, Meyskens FL. Inhibition of human malignant melanoma colony-forming cells in vitro by prostaglandin A1. Cancer Res. 1983 Apr; 43(4):1642-5. PMID: 6572555.
      View in: PubMed
    236. Neifeld JP, Tormey DC, Baker MA, Meyskens FL, Taub RN. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients. Cancer Treat Rep. 1983 Feb; 67(2):155-7. PMID: 6825122.
      View in: PubMed
    237. Kummet T, Moon TE, Meyskens FL. Vitamin A: evidence for its preventive role in human cancer. Nutr Cancer. 1983; 5(2):96-106. PMID: 6359074.
      View in: PubMed
    238. Persky B, Peters EM, Gehlsen KR, Sorrentino JM, Meyskens FL, Hendrix MJ. Scanning and transmission electron microscopic evaluation of human melanoma cells treated with adriamycin and actinomycin D. Scan Electron Microsc. 1983; (Pt 2):983-95. PMID: 6635583.
      View in: PubMed
    239. Ahmann FR, Meyskens FL, Moon TE, Durie BG, Salmon SE. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. Cancer Res. 1982 Nov; 42(11):4495-8. PMID: 6897012.
      View in: PubMed
    240. Persky B, Thomson SP, Meyskens FL, Hendrix MJ. Methods for evaluating the morphological and immunohistochemical properties of human tumor colonies grown in soft agar. In Vitro. 1982 Nov; 18(11):929-36. PMID: 6759369.
      View in: PubMed
    241. Thomson SP, Meyskens FL. Method for measurement of self-renewal capacity of clonogenic cells from biopsies of metastatic human malignant melanoma. Cancer Res. 1982 Nov; 42(11):4606-13. PMID: 7127298.
      View in: PubMed
    242. Surwit EA, Graham V, Droegemueller W, Alberts D, Chvapil M, Dorr RT, Davis JR, Meyskens FL. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol. 1982 Aug 01; 143(7):821-3. PMID: 7048932.
      View in: PubMed
    243. Scott KF, Meyskens FL, Russell DH. Retinoids increase transglutaminase activity and inhibit ornithine decarboxylase activity in Chinese hamster ovary cells and in melanoma cells stimulated to differentiate. Proc Natl Acad Sci U S A. 1982 Jul; 79(13):4093-7. PMID: 6125941.
      View in: PubMed
    244. Meyskens FL, Gilmartin E, Alberts DS, Levine NS, Brooks R, Salmon SE, Surwit EA. Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep. 1982 Jun; 66(6):1315-9. PMID: 6211233.
      View in: PubMed
    245. Meyskens FL, Moon TE, Dana B, Gilmartin E, Casey WJ, Chen HS, Franks DH, Young L, Salmon SE. Quantitation of drug sensitivity by human metastatic melanoma colony-forming units. Br J Cancer. 1981 Dec; 44(6):787-97. PMID: 7326191.
      View in: PubMed
    246. Meyskens FL. Modulation of abnormal growth by retinoids: a clinical perspective of the biological phenomenon. Life Sci. 1981 May 21; 28(21):2323-7. PMID: 7019614.
      View in: PubMed
    247. Fuller BB, Meyskens FL. Endocrine responsiveness in human melanocytes and melanoma cells in culture. J Natl Cancer Inst. 1981 May; 66(5):799-802. PMID: 6262556.
      View in: PubMed
    248. Salmon SE, Meyskens FL, Alberts DS, Soehnlen B, Young L. Update on in vitro testing on new drugs in ovarian cancer and melanoma. Cancer Treat Rep. 1981 May-Jun; 65(5-6):532-3. PMID: 7195308.
      View in: PubMed
    249. Meyskens FL, Salmon SE. Inhibition of human tumor colony formation by retinoids. Ann N Y Acad Sci. 1981 Feb 27; 359:414. PMID: 6942692.
      View in: PubMed
    250. Salmon SE, Meyskens FL, Alberts DS, Soehnlen B, Young L. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):1-12. PMID: 7226159.
      View in: PubMed
    251. Meyskens FL, Salmon SE. Modulation of clonogenic human melanoma cells by follicle-stimulating hormone, melatonin, and nerve growth factor. Br J Cancer. 1981 Jan; 43(1):111-5. PMID: 6779847.
      View in: PubMed
    252. Meyskens FL, Soehnlen BJ, Saxe DF, Casey WJ, Salmon SE. In vitro clonal assay for human metastatic melanoma cells. Stem Cells. 1981; 1(1):61-72. PMID: 7348870.
      View in: PubMed
    253. Alberts DS, Chen HS, Salmon SE, Surwit EA, Young L, Moon TE, Meyskens FL. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Cancer Chemother Pharmacol. 1981; 6(3):279-85. PMID: 6172215.
      View in: PubMed
    254. Jones JF, Meyskens FL, Nagle RB. The human thymus. I. Partial characterization of nonlymphoid cells. Thymus. 1980 Dec; 2(3):147-63. PMID: 6258273.
      View in: PubMed
    255. Meyskens FL, Berglund EB, Saxe DF, Fuller BB, Pacelli LZ, Hall JD, Ray CG. Biological and biochemical properties of a human uveal melanocyte-derived cell line. In Vitro. 1980 Sep; 16(9):775-80. PMID: 6773878.
      View in: PubMed
    256. Meyskens FL, Fuller BB. Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. Cancer Res. 1980 Jul; 40(7):2194-6. PMID: 6770995.
      View in: PubMed
    257. Meyskens FL, Jones JF, Kiefer CA. Terminal deoxynucleotidyl transferase development in the postnatal human thymus. Pediatr Res. 1980 May; 14(5):780-1. PMID: 6966786.
      View in: PubMed
    258. Meyskens FL. Human melanoma colony formation in soft agar. Prog Clin Biol Res. 1980; 48:85-99. PMID: 7208529.
      View in: PubMed
    259. Meyskens FL, Voakes JB. Tamoxifen in metastatic malignant melanoma. Cancer Treat Rep. 1980 Jan; 64(1):171-3. PMID: 7379053.
      View in: PubMed
    260. Salmon SE, Alberts DS, Meyskens FL, Durie BG, Jones SE, Soehnlen B, Young L, Chen HS, Moon TE. Clinical correlations of in vitro drug sensitivity. Prog Clin Biol Res. 1980; 48:223-45. PMID: 7193872.
      View in: PubMed
    261. Meyskens FL, Salmon SE. Inhibition of human melanoma colony formation by retinoids. Cancer Res. 1979 Oct; 39(10):4055-7. PMID: 476643.
      View in: PubMed
    262. Meyskens FL, Kiefer CA, Holmes DK, Gerner EW. Separation of normal human bone marrow cells by counterflow centrifugal elutriation. I. Morphological analysis and subfractionation of neutrophilic granulocytes. Exp Hematol. 1979 Sep; 7(8):401-10. PMID: 510435.
      View in: PubMed
    263. Meyskens FL, Jones SE. Terminal transferase: its evolving role. N Engl J Med. 1978 Apr 13; 298(15):845-6. PMID: 273144.
      View in: PubMed
    264. Gallo RC, Meyskens FL. RNA tumor viruses and human leukemia. Compr Ther. 1978 Feb; 4(2):42-8. PMID: 624212.
      View in: PubMed
    265. Meyskens FL, Tormey DC, Neifeld JP. Male breast cancer: a review. Cancer Treat Rev. 1976 Jun; 3(2):83-93. PMID: 782703.
      View in: PubMed